- 24 h
- 7 Tage
- 14 Tage
- 6 Monate
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02:42 | Eupraxia Pharmaceuticals Inc: Eupraxia releases first set of Resolve clinical results | 1 | Stockwatch | ||
| 02:06 | Cizzle Brands Corp: Cizzle's Cwench becomes Senators' official sports drink | 1 | Stockwatch | ||
| 02:00 | WUXI XDC (02268): CONNECTED TRANSACTION IN RELATION TO SUBSCRIPTION OF NEW SHARES UNDER SPECIFIC MANDATE | 1 | HKEx | ||
| 01:54 | Eisai, Biogen begin FDA submission for Alzheimer's autoinjector | 3 | Investing.com | ||
| 01:54 | Theratechnologies Inc (2): Theratechnologies shareholders urged to support FP deal | 1 | Stockwatch | ||
| 01:46 | Biogen Inc.: Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status | 256 | GlobeNewswire (Europe) | LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive... ► Artikel lesen | |
| 01:18 | Cybin Inc (2): Cybin CEO Drysdale steps down; So appointed in interim | 6 | Stockwatch | ||
| 01:15 | CLINUVEL PHARMACEUTICALS LIMITED: Date of Annual General Meeting | 3 | ASX | ||
| 00:26 | WUXI XDC (02268): PLACING OF NEW SHARES UNDER GENERAL MANDATE | 2 | HKEx | ||
| Di | Bionxt Solutions Inc: Bionxt Solutions receives semaglutide API | 3 | Stockwatch | ||
| Di | Windtree Therapeutics: Aktionäre genehmigen Kapitalerhöhung und Aktienzusammenlegung | 3 | Investing.com Deutsch | ||
| Di | Defence Therapeutics Inc: Defence Therapeutics hires Phinney as business adviser | 2 | Stockwatch | ||
| Di | SAB BioTherapeutics files to sell 250M shares of common stock for holders | 1 | Seeking Alpha | ||
| Di | CYBIN INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Di | Raymond James bestätigt "Outperform"-Rating für Regeneron | 2 | Investing.com Deutsch | ||
| Di | Acumen Pharmaceuticals stellt auf Citi-Konferenz neue Alzheimer-Strategie vor | 3 | Investing.com Deutsch | ||
| Di | CYTOKINETICS INC - 8-K, Current Report | 1 | SEC Filings | ||
| Di | Regeneron stock rating reiterated at Outperform by Raymond James | 4 | Investing.com | ||
| Di | WINDTREE THERAPEUTICS INC /DE/ - 8-K, Current Report | 2 | SEC Filings | ||
| Di | Bruker launches $600 million mandatory convertible preferred stock offering | 10 | Seeking Alpha |
1 2 3 4 5 Weiter >>
- 24 h
- 7 Tage
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | Aktuelle Nachrichten | |||
|---|---|---|---|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS | 10 | - | -0,36 % | Novartis erhält Lizenzrechte für Parkinson-Behandlung von Arrowhead | DJ Novartis erhält Lizenzrechte für Parkinson-Behandlung von Arrowhead
Von Nicholas G. Miller
DOW JONES--Novartis hat einen potenziell milliardenschweren Deal für eine Parkinson-Behandlung... ► Artikel lesen | ||
| CYTOKINETICS | 9 | 1 | -0,47 % | AKTIONÄR-Tipp Cytokinetics hebt ab - die Hintergründe | Biotech-Aktien stehen wieder höher in der Gunst der Anleger. In AKTIONÄR-Ausgabe 35/25 wurden vier aussichtsreiche Werte vorgestellt, die derzeit besonders aussichtsreich sind. Mit von der Partie: Cytokinetics.... ► Artikel lesen | ||
| BIOGEN | 8 | 54 | +0,21 % | Milliardenmarkt Multiple Sklerose - BioNxt Solutions, Biogen, Merck KGaA, Novartis | Multiple Sklerose (MS) ist eine entzündliche und chronische Erkrankung des zentralen Nervensystems im Gehirn und Rückenmark des Menschen. Dabei greift das Immunsystem durch eine Fehlregulation die eigenen... ► Artikel lesen | ||
| AMGEN | 7 | 27 | -0,41 % | Amgen To Invest $600 Mln In State-of-the-Art Science & Innovation Center At U.S. HQ | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) Tuesay announced plans to invest over $600 million in a new, state-of-the-art center for science and innovation at its global headquarters in Thousand... ► Artikel lesen | ||
| ZYMEWORKS | 6 | 5 | 0,00 % | Zymeworks Inc.: Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager | VANCOUVER, British Columbia, Sept. 02, 2025(Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care... ► Artikel lesen | ||
| MAZE THERAPEUTICS | 6 | - | +5,73 % | Maze Therapeutics, Inc.: Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer | SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for... ► Artikel lesen | ||
| BIONXT SOLUTIONS | 5 | 4 | -1,58 % | Bionxt Solutions Inc: Bionxt Solutions receives semaglutide API | |||
| IDEAYA BIOSCIENCES | 5 | 3 | -2,73 % | IDEAYA Biosciences, Inc.: Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide | Servier and IDEAYA Biosciences enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US
Darovasertib is a small molecule developed... ► Artikel lesen | ||
| HOTH THERAPEUTICS | 5 | 2 | 0,00 % | Hoth Therapeutics, Inc.: Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards | NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced combined positive... ► Artikel lesen | ||
| MINERALYS THERAPEUTICS | 5 | 1 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen |
- Alle
| Unternehmen / Aktien | Aktueller Kurs | Ø Kursziel (Euro) | Potential (Euro) | kaufen | halten | verkaufen | |||
|---|---|---|---|---|---|---|---|---|---|
| NANOREPRO AG | 1,820 | 4,50 | +147 % | 1 | - | - | |||
| MARINOMED BIOTECH AG | 19,900 | 42 | +111 % | 1 | - | - | |||
| EVOTEC SE | 5,790 | 9,20 | +59 % | 7 | 3 | - | |||
| BIONTECH SE ADR | 86,80 | 117,06 | +35 % | 3 | 2 | - | |||
| SARTORIUS STEDIM BIOTECH SA | 172,45 | 226,50 | +31 % | 4 | 2 | - | |||
| QIAGEN NV | 40,190 | 50 | +24 % | 7 | - | - | |||
| CUREVAC NV | 4,594 | 4,34 | -6 % | - | 1 | - |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .